ARTL$2.21+1.84%
Artelo Biosciences, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$1.21M
Float & O/S:
Inst Own:
DilutionScan read 32 of ARTELO BIOSCIENCES, INC.'s SEC filings and found 13 warrant series, 5 convertibles, 2 ATM programs, 2 equity lines, 2 shelf registrations, 5 S-1 registrations and 7 completed offerings on file for ARTL. The latest dilution event on file is ATM sales on Aug 11, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
ARTL
Tiny cash pile, severe dilution overhang, delisting risk
- Business
- WeakNo revenue, $12.9M net loss, only $4.2M cash
- Stock risk
- High$1.3M cap, two reverse splits, warrants = 147% of shares
Snapshot
Artelo is a pre-revenue clinical-stage biotech with no products on the market. FY 2025 net loss was $12.9M with no revenue, and cash of $4.2M barely covers a few months of its $8.5M annual cash burn.
What's Happening Right Now
- : Artelo will present data on its FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain (Oct 26-30) and plans a Phase 1 multiple ascending dose study in Q4 2026; no new clinical data was disclosed.
- : On Oct 9, 2026, Artelo disclosed via 8-K that it is among roughly 180 Nasdaq companies below the SEC's new $5 million market-value listing threshold, which could trigger delisting proceedings if the rule takes effect.
- : Artelo was selected for its first company presentation at BIO-Europe 2026 (Nov 10) to recap ART26.12 data as a partnering pitch; no new data or deal was announced.
- : On Sep 23, 2026, Artelo filed a provisional patent for ART27.13 in obesity after obese mice lost ~20% body weight alone and ~40% combined with semaglutide; results are preclinical and may not translate to humans.
- : Artelo completed a 1-for-9 reverse stock split effective Aug 31, 2026, leaving about 547,774 shares outstanding, its second reverse split in the past year.
- : Artelo amended its 10-Q to disclose a FINRA arbitration from Craft Capital Management seeking an $880,000 fee and warrants over a terminated engagement, with Artelo countersuing for fraudulent inducement.
- : Sold $354K net / 43K shares through its at-the-market program, as stated for Jul 1, 2026 to Aug 11, 2026.
- : Sold 16K shares through its at-the-market program.
- : Registered $75.00M of securities for sale on Form S-3.
